
- Treats Adults
- Accepting New Patients
Jamal Rahaman, MD
Obstetrics and Gynecology, Gynecologic Oncology
About Me
Jamal Rahaman, MD, MB BS, DGO, FACS, FACOG.
Dr. Rahaman is a Clinical Professor in the Division of Gynecologic Oncology. He has served as the Fellowship Program Director and the Director of the Gynecologic Oncology Chemotherapy Service at the Mount Sinai Medical Center. He has also previously served as the Division Director of Gynecologic Oncology at the Mount Sinai and Elmhurst Hospitals. He is one of a very few surgeons credentialed to teach and perform da Vinci Robotic Surgery for Gynecologic cancers and near-Infrared fluorescence sentinel lymph node mapping. He established the Training Program in Robotic Surgery for Gynecologic Cancers and regained full accreditation for the Gynecologic Oncology Fellowship Program from ABOG during his tenure as Fellowship Director. In 2017 he was appointed as a Governor of The American College of Surgeons and currently serves on the Surgical Training Workgroup and in the Education Pillar and in 2021 also appointed as the New York State Commission on Cancer Chair. In 2022 he was elected President of the Association of Attending Staff at Mount Sinai Hospital and serves on the Administrative Executive Committee of the Mount Sinai Medical Board.
Dr. Rahaman received his medical training at The University of the West Indies and did his first Residency in Obstetrics and Gynecology at The Mount Hope Women's Hospital, in a Royal College of Obstetricians & Gynecologists Program. He also completed the full Residency in Obstetrics and Gynecology at The Mount Sinai Medical Center. In addition to the Fellowship training in Gynecologic Oncology at Mount Sinai, he also completed a two-year Fellowship in Cardiac and Vascular surgery with Dr. Denton Cooley at the Texas Heart Institute. After serving as Chairman of The Department of Obstetrics & Gynecology at the Williamson ARH Hospital in Kentucky, he was recruited to return to the Faculty at Mount Sinai in the Division of Gynecologic Oncology.
Dr. Rahaman's academic responsibility focuses on the comprehensive training of subspecialty fellows in Gynecologic Oncology in addition to teaching resident physicians and medical students. He is widely recognized for his special expertise in complicated and challenging pelvic surgery especially laparoscopic, minimally invasive surgery and daVinci Robotic surgery. He is the principal and co-investigator on several National & International Clinical trials for gynecologic cancers including GOG chemotherapy trials and HPV vaccination trials. Dr. Rahaman is also engaged in basic science and translational research to identify potential predictors of malignant transformation to ovarian cancers as well as investigating novel targets and pathways for emerging cancer therapeutic agents. He has authored numerous publications in international journals and authored several book chapters in Gynecologic Oncology and has been the recipient of many teaching and peer recognition awards. His clinical practice encompasses the full spectrum of care for gynecologic cancers including Radical Surgery, Robotics, Argon Beam Laser, chemotherapy, and biologic therapy. He is also a certified colposcopist for Cervical Dysplasia clinical trials and provides complete treatment for pre-invasive lower genital tract disease including laser therapy.
Related Link:
Mount Sinai Gynecologic Oncology Fellowship Program
Areas of Cancer Focus include: Ovarian Cancer, Fallopian Tube Carcinoma, Uterine Cancer, Cervical Cancer, Germ Cell Tumors, Vaginal Cancer
Areas of Surgical Focus include: Hysterectomy, Minimally Invasive Hysterectomy, Laparoscopy, Oophorectomy, Exploratory Laparotomy, Lymph Node Biopsy, Ovarian Cyst Removal, Cystectomy, Lysis Of Adhesions, Dilation And Curettage, Cystoscopy
Areas of Clinical Focus include: Gynecologic Malignancies, Minimally Invasive Gynecologic Surgery, Pelvic Mass, Ovarian Cyst, Genetic Screening, BRCA, Clinical Trials, Chemotherapy, Ascites, Cervical Dysplasia, Cervical Conization, Loop Electrosurgical Excision Procedure, Colposcopy
Language
English
Position
CLINICAL PROFESSOR | Obstetrics, Gynecology and Reproductive Science
Hospital Affiliations
- The Derfner Foundation Ambulatory Surgery Center
- The Mount Sinai Hospital
Research Topics
Angiogenesis, Anti-Tumor Therapy, Cancer, Cancer Genetics, Clinical Genomics, Gene Expressions, Gene Regulation, Genomics, Metastasis, Molecular Biology, Oncogenes, Personalized Medicine, Positron Emission Tomography, Robotic Surgery, Translational Research, Tumor Suppressor Genes, Tumorigenesis
Multi-Disciplinary Training Areas
Cancer Biology [CAB]
Clinical Focus
- Abnormal Uterine Bleeding
- Adenomyosis
- Ascites
- Biopsy
- Cancer Fatigue
- Cancer Pain Syndromes
- Cervical Cancer
- Cervical Conization
- Cervical Cryosurgery
- Cervical Dysplasia
- Cervical Polyp
- Colposcopy
- Cystectomy
- Cystoscopy
- Dilation And Curettage
- Endometrial Biopsy
- Endometrial Cancer
- Endometrial Hyperplasia
- Endometrial Intraepithelial Neoplasia
- Endometriosis
- Endometriosis (Hormone Imbalance)
- Exploratory Laparotomy
- Fallopian Tube Carcinoma
- Fibroids
- Genetic Screening
- Germ Cell Tumors
- Gynecologic Biopsy
- Gynecologic Malignancies
- Heavy Menstrual Bleeding
- Human Papillomavirus Testing
- Hysterectomy
- Hysteroscopy
- Laparoscopy
- Leep
- Loop Electrosurgical Excision Procedure
- Lymph Node Biopsy
- Lynch Syndrome
- Lysis Of Adhesions
- Minimally Invasive Excision of Endometriosis
- Minimally Invasive Fibroid Removal
- Minimally Invasive Gynecologic Surgery
- Minimally Invasive Hysterectomy
- Myomectomy
- Oophorectomy
- Ovarian Cancer
- Ovarian Cancer Screening
- Ovarian Carcinoma
- Ovarian Cyst
- Ovarian Cyst Removal
- Pelvic Mass
- Pelvic Venous Congestion Syndrome
- Post-Menopausal Bleeding
- Uterine Cancer
- Uterine Fibroids
- Uterine Sarcoma
- Vaginal Cancer
- Vulvar Biopsy
- Vulvar Cancer
Education
MD, University of the West Indies-Jamaica
Residency, Obstetrics & Gynecology
Mount Hope Maternity Hospital
Residency, Obstetrics & Gynecology
Lincoln Medical and Mental Health Center
Residency, Obstetrics & Gynecology
Mount Sinai Hospital
Fellowship, Thoracic Surgery (Cardiothoracic Vascular Surgery)
The Texas Heart Institute
Fellowship, Gynecologic Oncology
Mount Sinai Hospital
Certifications
American Board of Obstetrics and Gynecology
Awards
2010
Sydney Druce Award
Department of Obstetrics & Gynecology at Mount Sinai
2008
Best Doctors in New York
New York Magazine
2008
Marquis-Who's Who in America
2007
Biltmore Who's Who
2007
Top Doctor
US News & World Report
2007
Super Doctor
New York Times
2002
Top Doctors in New York Metro Area
Castle Conolly Medical
2002
1st Place
ACOG Annual Meeting Film Festival
2002
Top Minimal Invasive Surgeons
New York Magazine
2001
CREOG/ACOG National Faculty Teaching Award for Residency Education
1990
Resident of the Year Award
Lincoln Medical Center
1984
Class Prize in Internal Medicine
1984
Leonard de Cordova Medal in Physiology
1984
Noel Haye Prize in Anatomy
1979
University of the West Indies Open Scholarship
1979
Trinidad and Tobago National Scholarship
Research
Active Clinical Trials
GOG0218 A Phase III Trial of Carboplatin and Paclitaxel plus placebo versus Carboplatin and Paclitaxel plus concurrent Bevacizumab (NSC # 704865, IND #7921) followed by placebo, versus Carboplatin and Paclitaxel plus concurrent and extended Bevacizumab, in women who are newly diagnosed, previously untreated, Stage III or IV, epithelial overian or primary peritoneal cancer NCI-supplied agent(s): Bevacizumab/Placebo (NSC #704865, IND #7921)
GOG0213 A Phase III randomized controlled clinical trial of Carboplatin and Paclitazel alone or in combination with Bevacizumab (NSC #704865, IND #7921) followed by Bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritone primary and fallopian tube cancer. NCI-supplied agents: Bevacizumab (NSC #704865, IND #7921)
GOG0212 A randomized phase III trial of maintenance chemotherapy comparing 12, monthly cycles of single agent Paclitaxel or CT-2103 (IND #70177), versus no treatment until documented relapse in women with advanced ovarian or primary peritoneal cancer achieve a complete clinical response to primary platinum/taxane chemotherapy
GOG0209 A Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer
GOG0210 A Molecular Staging Study of Endometrial Carcinoma
GOG0233 / ACRIN 6671 Utility of preoperative FDG-PET/CT and Ferumoxtran-10 MRI scanning prior to primary chemoradiation therapy to detect retroperitoneal lymph node metastasis in patients with locoregionally advanced (IB2, IIA ≥4 CM, IIB-IVA) carcinoma of the cervix
GOG0215 A Phase II Randomized Study of the Effect of Zoledronic Acid versus Observation on Bone Mineral Density of the Lumbar Spine in Women who Elect to Undergo Risk-Reducing Surgery that Results in Removal of Both Ovaries
GOG0136 Acquisition of human gynecologic specimens and serum to be used in studying the causes, diagnosis, prevention and treatment of cancer
GCO# 06-0832 Investigator Initiated Phase I/II trial of combination intra-peritoneal Docetaxel and intravenous pegylated liposomal doxorubicin in persistent epithelial ovarian, peritoneal and fallopian tube carcinoma.
GCO # 04-0754 A Phase lll, Double-Blind, Randomized, Controlled, Multi-Center, Study to Evaluate the Efficacy of GlaxoSmithKline Biologicals ' HPV-16/18 VLP/AS04 Vaccine Compared to Hepatitis A Vaccine as Control in Prevention of Persistent HPV-16 or HPV-18 Cervical Infection and Cervical Neoplasia, Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Females 15-25 Years of Age
Protocol 580299/008
GCO # 07-0267 A Phase lllb, Observer-Blind, Randomized, Multicenter Study With Two Parallel Groups to Compare the Immunogenicity of GlaxoSmithKline Biological 's HPV-16/18 L 1/AS04 Vaccine Versus Merck 's Gardasil Vaccine When Administered Intramuscularly According to a 3-Dose Schedule in Healthy Adult Females 18-45 Years of Age
Protocol 108933 (HPV-010)
Translational Research
- KLF6 is a novel regulator of VEGF in Ovarian cancer cell lines.
- Utility of a novel microarray assessment of critical signaling pathways in ovarian cancer
- MicroRNA signatures in Human Ovarian cancer and response to chemotherapy.
- Comparative Genomic Hypridiztion (CGH) Predicts Time to Recurrence in Primary Ovarian Carcinoma.
- Combination anti-estrogen and proteosome inhibitor biologic therapy for uterine cancer.
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Rahaman has not yet completed reporting of Industry relationships.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.